KZIA — KAZIA THERAPEUTICS LTD
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1075880 ·
Australia
Last close
$13.20
Market Cap
$150.84M
52W High
$15.31
52W Low
$10.59
ADV30
188,356
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 71,112,533 | 69,459,980 | 24,645,494 |
| Jun 2025 | — | — | — | — | 6,061,000 | 4,345,000 | 14,362,000 |
| Dec 2024 | — | — | — | — | 17,912,000 | 3,064,308 | 21,719,543 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-145,609,696
Inventory
—
Receivables
$307,852
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,898,631
EBITDA
$-17,840,660
Free Cash Flow
$1,099,920
Enterprise Value
$80,273,912
Total Cash
$69,459,984
Total Debt
$98,807
Shares Out
11,426,899
Trailing EPS
$-7.46
Book Value
$2.94
ROE
-106.9%
ROA
-25.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 42,000 | -14,217,000 | -20,702,000 | 6,061,000 | 14,362,000 | — | -13,278,000 |
| Jun 2024 | 2,308,000 | -28,462,000 | -26,778,000 | 21,585,000 | 31,602,000 | — | -9,581,000 |
| Jun 2023 | 0 | -24,146,000 | -20,465,000 | 28,084,000 | 16,034,000 | — | -15,156,000 |
| Jun 2022 | 0 | -25,399,000 | -25,014,000 | 35,889,000 | 17,614,000 | — | -22,762,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.02
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $17.50 · spot: $13.20 · call volume: 19 · put volume: 17
Expected Move to 2026-11-20:
±$6.68
(50.57%) —
implied range
$6.52 –
$19.87
· ATM straddle on $12.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AARD | Aardvark Therapeutics, Inc. | $150.57M | $6.88 | — |
| NRXP | NRX Pharmaceuticals, Inc. | $149.37M | $3.45 | — |
| INDP | Indaptus Therapeutics, Inc. | $154.56M | $1.16 | — |
| TLSA | Tiziana Life Sciences Ltd | $146.35M | $1.15 | — |
| UNCY | Unicycive Therapeutics, Inc. | $146.28M | $5.34 | — |
News headlines (Yahoo Finance, 1h cache)
Kazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast Cancer
2026-07-28 11:30 · Yahoo
Kazia Therapeutics Appoints James Levine as Chief Financial Officer
2026-06-02 11:30 · Yahoo
Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
2026-05-26 11:30 · Yahoo
How Kazia Therapeutics Ltd (KZIA) Is Strengthening Its Team and Platform
2026-04-28 17:30 · Yahoo
Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform
2026-04-15 12:00 · Yahoo
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform
2026-04-13 21:05 · Yahoo
Glioma Market is Set for Tremendous Growth at a CAGR of 15% During the Study Period (2022–2036), as Novel Targeted Therapies and Immunotherapies are Gaining Momentum | DelveInsight
2026-08-10 17:00 · Yahoo
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
2026-01-30 13:00 · Yahoo
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
2026-01-27 13:00 · Yahoo
US Equity Futures Mixed Pre-Bell Monday Despite Oil Sector Surge
2026-01-05 13:51 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.